Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

NCT03113422 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma
Non-Hodgkin's Lymphoma Follicular
Non-Hodgkin's Lymphoma, Adult High Grade

Interventions

DRUG: Induction Venetoclax
DRUG: Maintenance Venetoclax

Sponsor

PrECOG, LLC.

Collaborators

[object Object]